Chun-Ming Tsai

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler et al. · The Lancet Oncology · 2015 · 1.6K citations

Medicine, Oncology, Pharmacology +13

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne et al. · The Lancet Oncology · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +11

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

James Chih‐Hsin Yang, Lecia V. Sequist, Sarayut Lucien Geater et al. · The Lancet Oncology · 2015 · 982 citations

Medicine, Oncology, Pharmacology +16

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

Karen Kelly, Nasser K. Altorki, Wilfried Eberhardt et al. · Journal of Clinical Oncology · 2015 · 485 citations · Full text

Medicine, Oncology, Pharmacology +14

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su et al. · The Lancet Oncology · 2012 · 405 citations

Medicine, Oncology, Pharmacotherapy +13